Impact of primary tumour location and RAS/BRAF mutational status in metastatic colorectal cancer treated with first-line regimens containing oxaliplatin and bevacizumab: Prognostic factors from the AIO KRK0207 first-line and maintenance therapy trial

Impact of primary tumour location and RAS/BRAF mutational status in metastatic colorectal cancer treated with first-line regimens containing oxaliplatin and bevacizumab: Prognostic factors from the AIO KRK0207 first-line and maintenance therapy trial

Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: European Journal of Cancer - Volume 101, September 2018, Pages 105-113

Susanna Hegewisch-Becker, Stefanie Nöpel-Dünnebacke, Axel Hinke, Ullrich Graeven, Anke Reinacher-Schick, Jan Hertel, Christian A. Lerchenmüller, Birgitta Killing, Reinhard Depenbusch, Salah-Eddin Al-Batran, Thoralf Lange, Georg Dietrich,